Intramuscular Ephedrine in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia

• Status: Recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Subarachnoid anesthesia is an alternative and usually the first choice for many surgical procedures. It is a simple and safe procedure, however it can present complications such as hypotension and bradycardia. In this sense, ephedrine, an alpha and beta agonist agent, commonly used as rescue therapy for these events, is also potentially useful for prophylaxis of this unwanted effect and for less hemodynamic variation when preventively administered via the intramuscular route. Two groups will be divided: intramuscular ephedrine (0.5 mg/kg) and placebo. The variables analyzed and compared will be the incidence of hypotension and bradycardia, variation in mean and systolic blood pressure, heart rate, in addition to side effects. The main objective is to verify if the use of intramuscular ephedrine prior to spinal block is able to reduce the incidence of hypotension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Base
• Treatments: Ephedrine

Criteria

Inclusion Criteria:

• Patients over 18 years old, electively scaled for surgery requiring neuraxial block, with programming of spinal anesthesia.

• Physical State 1, 2 or 3 of the American Society of Anesthesiology (ASA)

Exclusion Criteria:

• Patients taking prophylactic or therapeutic anticoagulation, except respecting the allowed range;

• Patients with atrioventricular block

• Patients with cardiac arrhythmias

• Patients with heart failure;

• Patients with renal disease

• Patients with liver disease

• Patient carrying or suspecting any type of systemic infection or located in a puncture site;

• Patients who refuse to participate in the study after presenting the free and informed consent form;